Late-Breaking Abstracts

Late-Breaking Abstract Submission

Abstract submission deadline (incl. background information and methods) will be extended until 7th February 2022.

Submit your results and conclusion by Monday, April 4, 2022.

If an updated abstract is not submitted by that date, the abstract will be automatically rejected

Submission guidelines

In order for an abstract to be considered for Late-Breaking Abstract status, the submitting author must:

  • Submit an abstract, including the objectives and methods but excluding the results and conclusions of the research, by the submission deadline of January 31, 2022 – new deadline: 7th February 2022
  • Include any information that supports the potential for late-breaking impact.
  • If you would like your abstract to be considered late breaking, you must, contact Tara Mammoser once you submit prior to the January 31, 2022, deadline. Please be sure to include the abstract ID and title.

Important information:

Please note that only a limited number of abstracts (not to exceed six) from this Late-Breaking category will be selected for oral presentation at the meeting. Authors should note the following important information before submitting a Late-Breaking Abstract:  

  • Late-Breaking abstracts will be considered for oral presentation only.
  • Late-Breaking abstracts accepted for oral presentation will not be included in the regular abstract supplement to Neuro-Oncology and will be published electronically.
  • Late-Breaking abstracts not accepted for presentation will not be considered for any type of presentation format (poster, poster discussion or oral) and will not be part of the annual meeting program.
  • Late-Breaking abstracts will not be considered for awards.

This category is not intended to offer a second deadline for regular abstract submissions.

Submission categories

ISPNO welcomes submission of original research on the following topics:

• Craniopharyngioma and Rare Tumors
• Diffuse Midline Glioma/DIPG
• Drug Delivery/Pharmacokinetics
• Early Phase Clinical Trials
• Ependymoma
• Epidemiology
• ETMR and other Embryonal Tumors
• Germ Cell Tumors
• High Grade Glioma
• Imaging
• Immunotherapy
• Low Grade Glioma
• Medulloblastoma
• Neurofibromatosis and other Predisposition Syndromes
• Neuropsychology/Quality of Life
• Neurosurgery
• Nursing
• Others (not fitting any other category)
• Pathology/Classification
• Pediatric Neuro-Oncology in Low/Middle Income Countries
• Preclinical Models/Experimental Therapy/Drug Discovery
• Radiation Oncology
• Social Work/Patient Support/Palliative Care
• Tumor Biology (not fitting a specific disease category)
• Viral/Gene Therapy and other Novel Therapies